PSMA PET Imaging’s Proliferation Produces Uptick in Aggressive Treatment for Prostate Cancer

Why It Matters

The findings highlight a potential overuse of expensive systemic therapies driven by more sensitive imaging, posing challenges for value‑based care and prompting insurers to reassess coverage policies.

Key Takeaways

• PSMA PET use rose to surpass bone scans by 2023
• PSMA PET patients had double odds of receiving androgen‑receptor inhibitors
• Systemic therapy use was 10 points higher with PET versus bone scan
• Radical prostatectomy rates fell, radiotherapy rates rose for PET‑imaged patients
• Study warns higher costs without proven survival benefit from earlier treatment

Pulse Analysis

The rollout of PSMA PET imaging has reshaped prostate‑cancer diagnostics across the United States. Unlike traditional bone scans, the molecular scan pinpoints metastatic lesions with greater precision, enabling clinicians to stage disease earlier. This diagnostic leap has been embraced quickly by providers, especially within large payer networks, where claims data now show PSMA PET overtaking bone scans as the preferred initial imaging modality for advanced cases by 2023. The technology’s promise of improved detection, however, comes with a steep price tag and a learning curve for treatment decision‑making.

A recent JAMA Oncology study leveraging Blue Cross Blue Shield claims examined nearly 6,000 beneficiaries diagnosed between 2021 and 2023. Patients who underwent PSMA PET were twice as likely to receive androgen‑receptor pathway inhibitors—a class of drugs that can cost tens of thousands of dollars per year—and exhibited a 10‑percentage‑point increase in overall systemic therapy use. Surgical approaches also shifted, with a drop in radical prostatectomy rates and a rise in both primary and secondary radiotherapy. While these patterns suggest more aggressive management, the analysis could not link imaging‑driven treatment to longer survival or better quality of life, raising questions about cost‑effectiveness.

For payers, providers, and policymakers, the study underscores the tension between cutting‑edge diagnostics and value‑based care. As PSMA PET becomes standard, insurers may need to refine coverage criteria to avoid unnecessary escalation of expensive therapies lacking proven outcome benefits. Clinicians, meanwhile, must balance the allure of early intervention against the potential for overtreatment and cumulative toxicity. Ongoing prospective trials will be critical to determine whether the earlier, imaging‑guided treatment truly translates into meaningful clinical gains, informing future reimbursement and guideline decisions.